Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Warrant (NQ:BIAFW)

0.0700 +0.0100 (+16.67%)
Streaming Delayed Price Updated: 10:16 AM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 194
Open 0.0700
Bid (Size) 0.0700 (4)
Ask (Size) 0.1038 (4)
Prev. Close 0.0600
Today's Range 0.0700 - 0.0700
52wk Range 0.0525 - 2.490
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
bioAffinity Technologies Appoints New Members to Board of Directors
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
From bioAffinity Technologies, Inc.
Via Business Wire

Performance

YTD
-76.6%
-76.6%
1 Month
-56.2%
-56.2%
3 Month
-64.0%
-64.0%
6 Month
-88.3%
-88.3%
1 Year
-96.0%
-96.0%

More News

Read More
bioAffinity Technologies Reports Second Quarter 2025 Results
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
From bioAffinity Technologies, Inc.
Via Business Wire
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports First Quarter 2025 Results
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of $3.25 Million Offering
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence
From bioAffinity Technologies, Inc.
Via Business Wire
Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth
From bioAffinity Technologies, Inc.
Via Business Wire

Frequently Asked Questions

Is bioAffinity Technologies, Inc. - Warrant publicly traded?
Yes, bioAffinity Technologies, Inc. - Warrant is publicly traded.
What exchange does bioAffinity Technologies, Inc. - Warrant trade on?
bioAffinity Technologies, Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for bioAffinity Technologies, Inc. - Warrant?
The ticker symbol for bioAffinity Technologies, Inc. - Warrant is BIAFW on the Nasdaq Stock Market
What is the current price of bioAffinity Technologies, Inc. - Warrant?
The current price of bioAffinity Technologies, Inc. - Warrant is 0.0700
When was bioAffinity Technologies, Inc. - Warrant last traded?
The last trade of bioAffinity Technologies, Inc. - Warrant was at 08/22/25 10:16 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.